Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

The country’s Medicines and Healthcare products Regulatory Agency’s Yellow Card scheme, the UK’s official system for ...

To date, almost 400 reports of acute pancreatitis have been received from people using GLP-1 drugs such as Mounjaro, Wegovy, ...

New research shows most patients quit weight loss medications within 12 months. High costs and limited insurance coverage ...

Weight-loss drugs like Ozempic, while revolutionary, are under scrutiny as the UK's MHRA investigates serious pancreas ...

I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...

There are some potential downsides though, including misuse by those who do not need to lose weight, some gastric side-effects and in limited cases, potentially pancreatitis and gall bladder disorders ...

Delhi High Court asks drug regulator to look into concerns over approval for weight-loss drugs A PIL has claimed that licences for these drugs were issued without adequate data or India-specific ...

CVS is set to drop Zepbound as a medicine, but will continue to carry other popular weight loss drugs instead.

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

Novo Nordisk has submitted a new, higher dose of its obesity treatment, Wegovy, for approval to the European Medicines Agency ...